Analytical Data
-
Gene name
ACVR2B
- Application
-
Alternative Names
ACVR2-B; ActR-IIB
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P27040
-
Expression Region
Leu214~Asn350
-
Molecular Weight
17kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACVR2B, a member of the activin receptor family, has gained significant attention in the field of biomedical research due to its critical role in regulating various biological processes, including muscle development, tissue repair, and inflammation. This protein functions as a receptor for activin and myostatin, which are involved in the negative regulation of muscle growth. Dysregulation of ACVR2B signaling has been implicated in conditions such as muscle wasting disorders, cachexia, and certain cancers, making it a potential therapeutic target. Researchers have focused on developing recombinant ACVR2B proteins to study its signaling pathways and interactions, as well as to explore its potential in enhancing muscle mass in clinical settings. Recombinant forms of ACVR2B have shown promise in preclinical studies, demonstrating the ability to modulate muscle growth and improve outcomes in various disease models. Understanding the mechanisms of ACVR2B and its associated pathways may lead to innovative treatments for muscle-related diseases and other metabolic disorders, highlighting the importance of ongoing research in this area.
